Allergen ImmunoTherapy (AIT) is so far the only available treatment able to reverse allergen-specific immune responses and induce long-term tolerance. In the last two decades, the treatment of allergic diseases (severe asthma, chronic rhinosinusitis with nasal polyps, chronic spontaneous urticaria, atopic dermatitis…) is enriched with the use of biological treatments that specifically target mediators of type 2 inflammation and suppress inflammatory activity in tissues. The possibility of combining these two therapeutic strategies to improve safety and efficacy of allergic diseases treatment and extend the applicability of AIT to high-risk clinical settings is a hot topic that deserves a clear position of EAACI. The main objective of the Task Force will be to systematically review the available literature on the topic in order to publish an Evidence-Based EAACI Position Paper.

IG Allergen Immunotherapy

Chair: Enrico Heffler 

Secretary: Kymble Spriggs